Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2008-02-27
2011-12-06
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S045000, C514S266400
Reexamination Certificate
active
08071074
ABSTRACT:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
REFERENCES:
patent: 3634582 (1972-01-01), Hartley
patent: 4393053 (1983-07-01), Gonella
patent: 4904786 (1990-02-01), Musser et al.
patent: 5089516 (1992-02-01), Shiraishi et al.
patent: 5116616 (1992-05-01), Gonenne
patent: 5362755 (1994-11-01), Barberich et al.
patent: 5610288 (1997-03-01), Rubenstein
patent: 5667766 (1997-09-01), Wilson et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5760041 (1998-06-01), Wissner et al.
patent: 5801180 (1998-09-01), Takase et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5894018 (1999-04-01), Davila et al.
patent: 5932481 (1999-08-01), Pon et al.
patent: 5968748 (1999-10-01), Bennett et al.
patent: 6288082 (2001-09-01), Wissner et al.
patent: 6551989 (2003-04-01), Nadel et al.
patent: 6602863 (2003-08-01), Bridges et al.
patent: 6627634 (2003-09-01), Himmelsbach et al.
patent: 760766 (2000-03-01), None
patent: 1792207 (1971-11-01), None
patent: 4117078 (1992-11-01), None
patent: 4310051 (1993-10-01), None
patent: 0635498 (1995-01-01), None
patent: 0635507 (1999-09-01), None
patent: W090/03374 (1990-04-01), None
patent: W092/18481 (1992-10-01), None
patent: WO 9221332 (1992-12-01), None
patent: WO 9508114 (1995-03-01), None
patent: WO-96/09294 (1996-03-01), None
patent: WO96/09294 (1996-03-01), None
patent: WO97/19065 (1997-05-01), None
patent: WO 9804133 (1998-02-01), None
patent: WO9816228 (1998-04-01), None
patent: WO99/32121 (1999-07-01), None
patent: WO9945009 (1999-10-01), None
patent: WO00/10588 (2000-03-01), None
patent: WO 00/51991 (2000-09-01), None
patent: WO0177104 (2001-10-01), None
Chambers et al. Ach. Dis. Child. (1980) 55: 73-74.
Lange et al. Thorax (1990); 45:579-585.
Pistelli et al. European Respi. J, 21 (2003) Suppl. 40, 10s-14s.
Lange et al. Am. Rev. Respiratory Dis, (1990) 141(30:613-617 Abstract only.
Kim (Eur. Resp. J (1997):10, 1914-1917).
Borowitz Review for Health Care Professionals of the Children's Medical Center 2(5) (1996) pp. 1-8.
Lund, V.J. Diagnosis and treatment of nasal polyps. British Medical Journal. 1995, vol. 311, No. 7017, pp. 1411-1414.
Kumar, et al. Cooperative interaction of autocrine and paracrine mitogens for airway epithelial cells. Cell Biology and Toxicology, 1998, vol. 14, pp. 293-299.
Molchanov, The Great Soviet Encyclopedia (1964) 1-3.
Amishma et al., “Expression of epidermal growth factor and epidermal growth factor receptor immunoraeactivity in the asthmatic human airway,”: American Journal of Respiratory and Critical Care Medicine, 1998, 157(6):1907-1912.
Branch, “A good antisense molecule is hard to find,” Trends Biochem. Sci., 1998, 23(2):45-50.
Burgel et al., “Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps,” Journal of Allergy and Clinical Immunology, 2000, 106(4):705-712.
Rooke, Stanley T., Antisense Research and Application, 1998, Chapter 1, pp. 1-50.
Crystal, “Transfer of genes to humans: early lessons and obstacles to success,” Science, 1995, 270(5235):404-410.
Desseyn et al., “Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat,” The Journal of Biological Chemistry, 1997, 272(6): 3168-3178.
Donato et al, “Tumor Necrosis Factor Modulates Epidermal Growth Factor Receptor Phosphorylation and Kinase Activity in Human Tumor Cells,” The Journal of Biological Chemistry, 1989, 264(34):20474-20481.
Friedman, “Overcoming the obstacles to gene therapy,” Sci Am., 1997, 276(6):96-101.
Goldstein et al., “Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model,” Clinical Cancer Research, 1995, 1:1311-1318.
Grandis et al., “Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not norml mucosal epithelial cells,” Oncogene, 1997, 15(4):409-416.
Guzman et al., “Epidermal growth factor regulates expression of the mucous phenotype of rat tracheal epithelial cells,” Biochem. Biophys. Res. Com., 1995, 217(2): 412-418.
Kawamoto et al., “Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors to epidermal growth factor by an anti-receptor monoclonal antibody,” Proc. Natl. Acad. Sci. USA, 1983, 80:1337-1341.
Kim et al., “Levels of Intracellular Protein and Messenger RNA of Mucin and Lysozyme in Normal Human Nasal and Polyp Epithelium,” The Laryngoscope, 2000, 110(2 pt. 1):276-280.
Kondapaka et al., “Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer,” Molecular and Cellular Endocrinology, 1996, 117:53-58.
Lee et al., “Epidermal growth factor receptor signaling mediates regranulation of rat nasal goblet cells,” Journal of Allergy and Clinical Immunology, 2001, 107(6):1046-1050.
Levitski, “Signal-transduction therapy, a novel approach to disease management”, Eur. J. Biochem., 1994, 226(1):1-13.
Lorimer, et al., “Immunotoxins that Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors,” Clinical Cancer Research, 1995, 1:859-864.
Nadel et al., “The role of epidermal growth factor in mucus production,” Current Opinion in Pharmacology, 2001, 1 (3):254-258.
Nadel, “Role of epidermal growth factor receptor activation in regulating mucin synthesis,” Respiratory Research, 2001, 2(2):85-89.
Petit et al., “Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2
eu Receptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells in Vitro and in Vivo,” American Journal of Pathology, 1997, 151(6):1523-1530.
Powis, “Signaling pathways as targets for anticancer drug development,” Pharmac. Ther., 1994, 62:57-95.
Schmidt et al., “Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGF.alpha.,” British Journal of Cancer, 1996, 74: 853-862.
Schofield et al., “Non-viral approaches to gene therapy,” British Medical Bulletin, 1995, 51(1):56-71.
Takeyama et al., “Epidermal growth factor system regulates mucin production in airways.” Proceedings of the national Academy of Sciences USA, 1999, 96(6):3081-3086.
Takeyama et al., “Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules,” Am. J. Physiol., 1998, 275:294-302.
Takeyama et al., “Oxidative stress causes mucin synthesis via transactivation of epdiermal growth factor receptor: role of neutorphils,” Journal of Immunology, 2000, 164(3):1546-1552.
Temann et al., “A Novel Role of Murine IL-4 In Vivo: Induction of MUC5AC Gene Expression and Mucin Hypersecretion,” Am J. Respir. Cell. Biol., 1997, 16:471-478.
Ullrich et al., “Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells,” Nature, 1984, 309(5967):418-425.
Van Herwaarden et al., “The role of N-acetylcpteine in the treatment of chronic obstmctive pulmonary disease,” Netherlands Journal of Medicine, 1995, 47:45-48.
Verma et al., “Gene therapy—promises, problems and prospects,” Nat
Nadel Jay A.
Takeyama Kiyoshi
Borden Paula A.
Bozicevic Field & Francis LLP
Fetterolf Brandon
Foulds Glenn
Gembeh Shirley V
LandOfFree
Preventing airway mucus production by administration of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventing airway mucus production by administration of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventing airway mucus production by administration of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301758